- Home
- XMTR vs DNLI Comparison
XMTR vs DNLI Comparison
Compare XMTR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XMTR | DNLI |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XMTR | DNLI |
|---|---|---|
| Price | $92.59 | $23.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $58.60 | $34.33 |
| AVG Volume (30 Days) | 778.3K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $686,631,000.00 | N/A |
| Revenue This Year | $23.76 | N/A |
| Revenue Next Year | $18.38 | $408.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.87 | N/A |
| 52 Week Low | $30.63 | $12.58 |
| 52 Week High | $99.86 | $24.21 |
Technical Indicators
Market Signals| Indicator | XMTR | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 66.55 | 68.33 |
| Support Level | $56.76 | $18.27 |
| Resistance Level | $99.86 | $23.62 |
| Average True Range (ATR) | 4.54 | 1.18 |
| MACD | -0.68 | 0.36 |
| Stochastic Oscillator | 70.88 | 77.28 |
Price Performance
Historical ComparisonAbout XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.